07:31 AM EDT, 06/20/2025 (MT Newswires) -- Exelixis ( EXEL ) said Friday that its partner Ipsen received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for Cabometyx, to treat adults with unresectable or metastatic, well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors.

The recommendation is based on results from a phase 3 trial comparing Cabometyx to placebo in two patient groups, the company said.

The European Commission will make a final decision on the recommendation in coming months, the company said.